RF IgG Test

If you have ever had joint pain, stiffness, or swelling and wondered whether your immune system might be attacking your own body, this test adds a layer of information that routine screening often skips. Standard rheumatoid factor (RF) testing typically measures only one type of autoantibody, the IgM version. RF IgG (rheumatoid factor immunoglobulin G) is a different class of the same autoantibody, and its presence can change how your results are interpreted, especially if the standard test comes back negative.

RF IgG is part of a family of autoantibodies (IgM, IgA, and IgG) that bind to the tail end of your body's own IgG antibodies. When your immune system produces these self-targeting antibodies, it can trigger inflammation and tissue damage, particularly in the joints. Knowing which types of RF you carry, and at what levels, gives a more complete picture of autoimmune risk than any single test alone.

How RF IgG Fits Into the Autoimmune Picture

Your immune system makes antibodies to fight infections. Rheumatoid factors are antibodies that mistakenly target your own antibodies instead. They bind to a region called the Fc portion of IgG, the most common antibody class in your blood. This binding creates clumps of antibodies called immune complexes, which can deposit in joints and blood vessels and drive chronic inflammation.

RF comes in three main types, named after the antibody class doing the targeting: IgM-RF (the one measured by standard tests), IgA-RF, and IgG-RF. Each type is produced by a different wave of immune cell activation. IgG-RF specifically reflects a more mature, sustained autoimmune response, because producing IgG-class antibodies requires the immune system to go through a process called class switching, where B cells (the immune cells that make antibodies) are repeatedly stimulated and refined over time.

In a study of about 1,600 people with early rheumatoid arthritis (RA), RF as a group was linked to higher levels of systemic inflammation, measured by markers like ESR (erythrocyte sedimentation rate, a blood test that measures how quickly red blood cells settle, reflecting inflammation) and CRP (C-reactive protein, another inflammation marker). This connection was independent of which classification criteria were used to diagnose RA, suggesting RF captures something real about how the immune system behaves in this disease.

Diagnostic Accuracy: What RF IgG Can and Cannot Tell You

RF IgG on its own is not a strong screening test for rheumatoid arthritis. In a large cohort of over 1,600 RA patients and controls, RF IgG had about 36% sensitivity (meaning it caught only about 36 out of every 100 people who actually had RA) and moderately high specificity. It had the weakest discrimination among the three RF types, with an AUC (area under the curve, a measure of overall test accuracy where 1.0 is perfect and 0.5 is no better than flipping a coin) of just 0.61.

A meta-analysis pooling data from over 7,500 RA patients found similar numbers: RF IgG sensitivity of about 40% and specificity of about 79%. By comparison, the standard IgM-RF test has sensitivity around 60 to 66% and specificity around 87 to 90%. Anti-CCP antibodies (also called ACPA, antibodies against citrullinated proteins, which are proteins modified by a chemical change associated with inflammation) have sensitivity around 60 to 70% but specificity above 97%.

What this means for you: RF IgG is not the test to order if you just want to know whether you have RA. Its real value emerges when combined with the other RF types and anti-CCP. When multiple autoantibody types are positive at the same time, the diagnostic odds for RA improve substantially compared with any single test. In one study, measuring all three RF isotypes together improved the ability to classify patients correctly, and a cohort of over 3,100 people showed that some patients classified as "seronegative" on standard testing actually carried IgG and IgA RF, with disease patterns resembling seropositive RA.

Rheumatoid Arthritis Risk

Most large prospective studies measuring RA risk have used total or IgM-RF rather than IgG-RF specifically, so the following findings need that context. In the Copenhagen City Heart Study, which followed over 9,700 adults for up to 29 years, people with IgM-RF above 100 IU/mL had about 26 times the risk of developing RA compared with those below 25 IU/mL. Even moderately elevated levels (50 to 100 IU/mL) carried about 6 times the risk. These associations remained strong after adjusting for age, sex, smoking, and other factors.

Whether IgG-RF carries the same predictive power for future RA is less well studied. In seropositive arthralgia cohorts (people with joint pain and positive autoantibodies but no confirmed RA yet), having multiple RF types positive, including IgG, was associated with disease patterns resembling established seropositive RA. A study of 305 at-risk individuals found that having both IgA-RF and IgM-RF positive roughly tripled the risk of developing RA, but IgG-RF was not separately analyzed for prediction in most of these cohorts.

Mortality and Cardiovascular Risk

The mortality data available is based on total or IgM-RF, not IgG-RF specifically. These findings are relevant context for understanding what RF positivity means broadly, but they should not be taken as direct evidence about what your IgG-RF result predicts.

In a South Korean cohort of nearly 296,000 adults without RA, those with total RF above 20 IU/mL had about 50% higher all-cause mortality and about 56% higher cancer mortality compared with RF-negative individuals. At levels above 100 IU/mL, all-cause mortality was roughly 2.7 times higher. Cardiovascular mortality, however, was not significantly different. In the Mayo Clinic RA cohort, RF-positive RA patients had 50% higher cardiovascular mortality and about 3.5 times higher respiratory mortality compared with the general population. RF-negative RA patients showed no excess mortality.

A Danish RA inception cohort of 509 patients followed for over 6,000 person-years found that excess mortality was concentrated in RF-positive males, who had about 47% higher overall mortality, 63% higher cardiovascular mortality, and more than double the cancer mortality compared with what would be expected in the general population.

Lung Disease in Rheumatoid Arthritis

RA can affect the lungs, causing a condition called interstitial lung disease (ILD), where inflammation and scarring develop in the lung tissue. In a U.S. Veterans RA registry of over 2,300 patients, having RF at low-positive levels (15 to 45 IU/mL) was associated with about 2.7 times the odds of having ILD at the time of enrollment, and high-positive RF (above 45 IU/mL) carried about 3.4 times the odds. For new cases of ILD developing over time, only very high RF (above 90 IU/mL) was significantly associated, with about 68% higher risk. These findings used total RF, not IgG-RF specifically.

When Results Can Be Misleading

The single biggest confounder for RF IgG is the test itself. Different laboratory methods can give dramatically different results on the same blood sample, and this problem is worse for IgG-RF than for IgM-RF.

• Assay target antigen: Some tests use human IgG as the target, while others use rabbit IgG. In one study of 274 samples, about 10% of people who tested RF-negative with a rabbit-IgG-based assay were clearly RF-positive when human IgG was used. If your lab uses a rabbit-IgG assay, a negative result does not rule out RF positivity.
• Detection method: ELISA, nephelometry, and turbidimetry (three different laboratory techniques for measuring antibody levels) can give systematically different RF values and may disagree on whether a sample is positive or negative, even when all use the same target antigen.
• Age: A population-based study of 810 adults found that levels of all three RF types shift with age. Age-specific reference values may be more appropriate than a single universal cutoff, but most labs do not provide them.
• Other autoimmune conditions: RF (including IgG-RF) can be positive in other autoimmune diseases, chronic infections, and even in a proportion of otherwise healthy older adults, which limits the test's specificity when used outside of a clinical context that already suggests RA.

RF can also interfere with other laboratory tests. In one study, RF-positive samples from patients with RA and lupus produced false positive results on most commercial SARS-CoV-2 antibody assays. If you are RF-positive, mention this to any provider interpreting infectious disease antibody tests.

Reference Ranges

Standardized clinical cutpoints for RF IgG do not exist in the way they do for RF IgM. Because RF IgG assays vary widely between manufacturers and methods, the numbers your lab reports may not be comparable to those from a different lab. The following are general orientations based on published research, not universal targets. Most ELISA-based RF IgG assays use a cutoff in the range of 20 to 25 IU/mL for positivity.

Always compare your results within the same lab over time. Switching labs can shift your result purely because of assay differences, not because anything changed in your body.

Tracking Your Trend

A single RF IgG result is a snapshot, not a verdict. Autoantibody levels can fluctuate, and a one-time positive does not confirm RA any more than a one-time negative rules it out. A 10-year follow-up study of 320 RA patients in Malaysia found that RF status (across all isotypes) changed over time in a meaningful proportion of patients. Some who were initially positive became negative, and vice versa.

If you are testing because of joint symptoms, get a baseline RF IgG (ideally alongside IgM-RF, IgA-RF, and anti-CCP), then retest in 3 to 6 months if the clinical picture is unclear. If you are already diagnosed with RA and tracking your autoantibody profile, annual retesting through the same lab gives the most reliable trend. If you are asymptomatic and testing proactively because of family history, a single negative result is reassuring but not definitive. Consider retesting every 1 to 2 years if you have a first-degree relative with RA.

What to Do With Your Result

If your RF IgG comes back positive, the next step is context, not panic. A positive result in isolation has limited meaning. The decision pathway depends on what else is going on.

• Positive RF IgG with joint symptoms: Order IgM-RF, IgA-RF, anti-CCP (CCP Antibody), hs-CRP (high-sensitivity C-reactive protein), and ESR (erythrocyte sedimentation rate) if not already done. If multiple autoantibodies are positive, especially anti-CCP, the probability of RA is high. A rheumatologist should evaluate you, ideally before joint damage begins.
• Positive RF IgG without symptoms: Retest in 3 to 6 months with a full autoantibody panel. If it remains positive and other markers are also positive, you may be in a preclinical phase. Research shows that autoantibodies can appear years before clinical RA develops. This is the window where monitoring can catch disease at its earliest, most treatable stage.
• Negative RF IgG with joint symptoms: Do not stop investigating. RF IgG has low sensitivity, so a negative result misses the majority of RA cases. IgM-RF and anti-CCP are better screening tests and should be checked.
• Negative RF IgG without symptoms: A reassuring result, but if you have strong family history of RA, periodic rechecking (every 1 to 2 years) is reasonable.

The specialist most likely to help interpret a complex autoantibody profile is a rheumatologist. If your RF IgG is positive alongside anti-CCP and elevated inflammatory markers, early referral matters. In RA, the first two years after symptom onset are a treatment window where aggressive therapy can prevent irreversible joint damage.